Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan Dubow

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Sleep Medicine: X|September 12, 2024
RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybatesAsim Roy, Thomas Stern, John Harsh, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 30, 2014
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label resultsHubert H Fernandez, David G Standaert, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 24, 2015
Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trialsAnthony E Lang, Ramon L Rodriguez, James T Boyd, et al.
The Lancet. Neurology|December 15, 2023
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trialAndrew McGarry, Shane Rosanbalm, Mika Leinonen, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Sleep Medicine: X|September 12, 2024
RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybatesAsim Roy, Thomas Stern, John Harsh, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 30, 2014
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label resultsHubert H Fernandez, David G Standaert, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 24, 2015
Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trialsAnthony E Lang, Ramon L Rodriguez, James T Boyd, et al.
The Lancet. Neurology|December 15, 2023
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trialAndrew McGarry, Shane Rosanbalm, Mika Leinonen, et al.
Pageof 3